SCHEMBL15035741

SCHEMBL15035741

Cc1ccccc1Oc1cc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n(Cc2cncn2S(C)(=O)=O)c1=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.52
WEE1 P30291 7/20 0.48
FGFR4 P22455 6/20 0.48
CDK4 P11802 3/20 0.46
CCND1 P24385 3/20 0.46
CCND2 P30279 3/20 0.46
CCND3 P30281 3/20 0.46
MAP3K7 O43318 1/20 0.45
MAPK1 P28482 1/20 0.45
MAP2K1 Q02750 1/20 0.45
PAK4 O96013 1/20 0.45
PAK1 Q13153 1/20 0.45
PKN1 Q16512 1/20 0.45
FGFR1 P11362 1/20 0.44
SRC P12931 1/20 0.44
FGFR2 P21802 1/20 0.44
FGFR3 P22607 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041388 0.93 MAPK8 (0.59) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15035780 0.83 MAPK8 (0.49) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15034887 0.82 MAPK8 (0.52) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15277127 0.81 FGFR4 (0.55) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15035010 0.80 MAPK8 (0.52) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15034778 0.80 MAPK8 (0.52) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15041429 0.76 MAPK8 (0.56) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15041366 0.75 MAPK8 (0.59) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15280129 0.74 MAPK8 (0.56) MAPK8WEE1FGFR4CDK4CCND1
SCHEMBL15035409 0.74 MAPK8 (0.54) MAPK8WEE1FGFR4CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK6 MAPK8 8/4885WEE1 983/4885FGFR4 2162/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 MAPK8 493/4885WEE1 545/4885FGFR4 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.